---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-22-000124"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2022-07-21T23:59:59+00:00"
generated_at: "2026-06-24T09:49:29.228970+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics appoints Chris Smith as CEO effective Aug 15, 2022; Tetrault resumes Chair

## Summary
- Chris Smith, former CEO of Ortho Clinical Diagnostics, appointed CEO effective August 15, 2022.
- Base salary $1M/year, target annual bonus 100% of salary, inducement awards ~$8.5M (RSUs and options).
- Interim CEO Lynn Tetrault steps down and resumes role as independent Chair of the Board.
- Smith led Ortho Clinical through its IPO ($1.45B) and Quidel merger; previously CEO of Cochlear (2015-2018).
- Relocation benefits up to $400K; severance: 1x salary+bonus (non-CIC) or 3x salary+bonus (CIC).

## SEC filing metadata
- accession: 0001077183-22-000124
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2022-07-21T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000124/0001077183-22-000124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000124/neo-20220720.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-22-000124
- JSON: https://secwatch.observer/filing/0001077183-22-000124.json
- Plain text: https://secwatch.observer/filing/0001077183-22-000124.txt

## Key facts
- Executive change
  Chris Smith was appointed as Chief Executive Officer at NEOGENOMICS INC.
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On July 21, 2022, NeoGenomics, Inc. (the “Company”) announced that Chris Smith, age 59, was appointed Chief Executive Officer and a member of the board of directors of the Company, effective August 15, 2022 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000124/0001077183-22-000124-index.htm
- Executive change
  Lynn Tetrault changed role as Chair of the Board at NEOGENOMICS INC.
  - Action: step down as Interim CEO and resume Chair
  - Role: Chair of the Board
  source text: In connection with Mr. Smith’s appointment, Lynn Tetrault, Esq. will step down as Interim Chief Executive Officer of the Company and will resume the position of independent Chair of the Board effective August 15, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000124/0001077183-22-000124-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.